drugset
drugset / Trial / NCT02209805

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

NCT02209805 ↗

Phase 1 Completed 49 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to assess the safety and pharmacokinetics of BIRB 796 BS tablets administered as multiple daily doses at various dose levels.

Timeline

Start
2001-01
Primary completion
2001-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIRB 796 BS Unknown 30 mg Oral
Subject BIRB 796 BS Unknown 60 mg Oral
Subject BIRB 796 BS Unknown 120 mg Oral

Indications

No indication recorded.